A landmark international study led by the University of Zurich (UZH) has demonstrated that artificial intelligence (AI) can evaluate patient risk for the most common type of heart attack more accurately than current methods. This breakthrough could help doctors tailor treatment decisions and provide more personalized care.
Limitations of Existing Risk Assessment
Patients suffering from non-ST-elevation acute coronary syndrome (NSTE-ACS)—the most common form of heart attack—have traditionally been assessed using the GRACE score. This standardized scoring system estimates patient risk and guides the timing of catheter-based interventions, such as angiography and stenting. The GRACE score is widely used and incorporated into international clinical guidelines.
However, clinicians have long recognized that existing tools cannot capture the full complexity of NSTE-ACS patients. Some patients may benefit significantly from early intervention, while others may not, highlighting the need for improved risk stratification.
Analyzing Data from Over 600,000 Patients
Published in The Lancet Digital Health, the new study represents the largest investigation of risk modeling in NSTE-ACS to date. Researchers analyzed health data from more than 600,000 patients across 10 countries. They applied AI to clinical trial data from the VERDICT trial, training the model to identify patients who would benefit most from early invasive treatment.
Re-Stratifying Patient Care
“The results were striking,” said Florian A. Wenzl, first author and researcher at UZH’s Center for Molecular Cardiology. “While some patients gained substantial benefit from early intervention, others showed little or no advantage.”
These findings suggest that current treatment strategies may sometimes target the wrong patients. As a result, hospitals worldwide may need to re-stratify patient care, assessing the individual benefit of established treatment strategies rather than applying a one-size-fits-all approach.
GRACE 3.0: AI-Powered Precision in Heart Attack Treatment
Using AI, the team developed GRACE 3.0, a new model that re-analyzes clinical trial data to determine which patients truly benefit from early invasive treatment. According to Wenzl, this tool has the potential to transform how clinicians manage heart attack patients, ensuring interventions are applied where they are most effective.
Thomas F. Lüscher, last author and researcher at UZH and the Royal Brompton and Harefield Hospitals in London, emphasized, “GRACE 3.0 is the most advanced and practical tool yet for treating patients with the most common type of heart attacks. It not only predicts risk more accurately but also guides personalized treatment decisions.”
Towards More Personalized and Effective Care
As reported by medicalxpress, the researchers hope that GRACE 3.0 will provide clinicians with a simple, validated, AI-powered tool for routine practice. By helping doctors identify which patients benefit from specific interventions, the model could reshape future clinical guidelines, improve patient outcomes, and save lives.
This study demonstrates the transformative potential of AI in cardiology, offering a pathway toward more precision-based and individualized care for heart attack patients.